Dexamethasone inhibits the HSV-tk/ ganciclovir bystander effect in malignant glioma cells

BackgroundHSV-tk/ ganciclovir (GCV) gene therapy has been extensively studied in the setting of brain tumors and largely relies on the bystander effect. Large studies have however failed to demonstrate any significant benefit of this strategy in the treatment of human brain tumors. Since dexamethasone is a frequently used symptomatic treatment for malignant gliomas, its interaction with the bystander effect and the overall efficacy of HSV-TK gene therapy ought to be assessed.MethodsStable clones of TK-expressing U87, C6 and LN18 cells were generated and their bystander effect on wild type cells was assessed. The effects of dexamethasone on cell proliferation and sensitivity to ganciclovir were assessed with a thymidine incorporation assay and a MTT test. Gap junction mediated intercellular communication was assessed with microinjections and FACS analysis of calcein transfer. The effect of dexamethasone treatment on the sensitivity of TK-expressing to FAS-dependent apoptosis in the presence or absence of ganciclovir was assessed with an MTT test. Western blot was used to evidence the effect of dexamethasone on the expression of Cx43, CD95, CIAP2 and BclXL.ResultsDexamethasone significantly reduced the bystander effect in TK-expressing C6, LN18 and U87 cells. This inhibition results from a reduction of the gap junction mediated intercellular communication of these cells (GJIC), from an inhibition of their growth and thymidine incorporation and from a modulation of the apoptotic cascade.ConclusionThe overall efficacy of HSV-TK gene therapy is adversely affected by dexamethasone co-treatment in vitro. Future HSV-tk/ GCV gene therapy clinical protocols for gliomas should address this interference of corticosteroid treatment.

[1]  J. Revel,et al.  Inhibition of gap junction and adherens junction assembly by connexin and A-CAM antibodies , 1992, The Journal of cell biology.

[2]  H. Möllmann,et al.  Pharmacokinetics and Pharmacodynamics of Dexamethasone Sodium‐m‐Sulfobenzoate (DS) after Intravenous and Intramuscular Administration: A Comparison with Dexamethasone Phosphate (DP) , 2001, Journal of clinical pharmacology.

[3]  S. Ylä-Herttuala,et al.  Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. , 2000, Human gene therapy.

[4]  C. Naus,et al.  Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. , 1997, Cancer research.

[5]  T. Burn,et al.  Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types. , 2002, Endocrinology.

[6]  T. Velu,et al.  Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-β-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase , 2000, Cancer Gene Therapy.

[7]  N. Rainov.  A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. , 2000, Human gene therapy.

[8]  K. Elisevich,et al.  In vivo growth of C6 glioma cells transfected with connexin43 cDNA. , 1992, Cancer research.

[9]  K. Willecke,et al.  Negative growth control of HeLa cells by connexin genes: connexin species specificity. , 1995, Cancer research.

[10]  M. Merville,et al.  Growth regulation of astrocytes and C6 cells by TGFβI: correlation with gap junctions , 2000, Neuroreport.

[11]  J. Wyatt,et al.  Antisense Oligonucleotide Inhibition of Bcl-xL and Bid Expression in Liver Regulates Responses in a Mouse Model of Fas-Induced Fulminant Hepatitis , 2003, Journal of Pharmacology and Experimental Therapeutics.

[12]  M. Merville,et al.  Modulation of the HSV-TK/ganciclovir bystander effect by n-butyrate in glioblastoma: correlation with gap-junction intercellular communication. , 2004, International journal of oncology.

[13]  D. Gros,et al.  Rat gap junction connexin-30 inhibits proliferation of glioma cell lines. , 2001, Carcinogenesis.

[14]  A. Benabid,et al.  Increased bax expression is associated with cell death induced by ganciclovir in a herpes thymidine kinase gene-expressing glioma cell line. , 1999, Human gene therapy.

[15]  S. Wei,et al.  Involvement of Fas (CD95/APO-1) and Fas ligand in apoptosis induced by ganciclovir treatment of tumor cells transduced with herpes simplex virus thymidine kinase , 1999, Gene Therapy.

[16]  M. Merville,et al.  HSV-1 thymidine kinase gene therapy for colorectal adenocarcinoma-derived peritoneal carcinomatosis , 1997, Gene Therapy.

[17]  S. Freeman,et al.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.

[18]  J. Cidlowski,et al.  Cell cycle regulation and apoptosis. , 1998, Annual review of physiology.

[19]  W. Ramsey,et al.  Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. , 1998, Human gene therapy.

[20]  Z. Ram,et al.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. , 1992, Science.

[21]  G. Moonen,et al.  Pharmacological modulation of the bystander effect in the herpes simplex virus thymidine kinase/ganciclovir gene therapy system: effects of dibutyryl adenosine 3',5'-cyclic monophosphate, alpha-glycyrrhetinic acid, and cytosine arabinoside. , 2000, Biochemical pharmacology.

[22]  S. Goldman,et al.  Curative potential of herpes simplex virus thymidine kinase gene transfer in rats with 9L gliosarcoma. , 1996, Human gene therapy.

[23]  J. Nagy,et al.  Connexin30 in rodent, cat and human brain: selective expression in gray matter astrocytes, co-localization with connexin43 at gap junctions and late developmental appearance , 1999, Neuroscience.

[24]  J. Cairncross,et al.  Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Warnick,et al.  Protein and messenger RNA expression of connexin43 in astrocytomas: implications in brain tumor gene therapy. , 1996, Journal of neurosurgery.

[26]  S. Orrenius,et al.  Dexamethasone pre-treatment interferes with apoptotic death in glioma cells , 2000, Neuroscience.

[27]  R. Ramesh,et al.  Immune system in suicide-gene therapy , 1997, The Lancet.

[28]  Z. Ram,et al.  Mechanism of ‘bystander effect’ killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment , 1997, Gene Therapy.

[29]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[30]  F. Moolten.  Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. , 1986, Cancer research.

[31]  J. Whang‐Peng,et al.  S- and G2-phase cell cycle arrests and apoptosis induced by ganciclovir in murine melanoma cells transduced with herpes simplex virus thymidine kinase. , 1998, Experimental cell research.

[32]  T. Takano,et al.  Connexin Mediates Gap Junction-Independent Resistance to Cellular Injury , 2003, The Journal of Neuroscience.

[33]  S. Fulda,et al.  Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Davidson,et al.  Superior cytotoxicity with ganciclovir compared with acyclovir and 1-beta-D-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing. , 1998, Cancer research.

[35]  K. Willecke,et al.  Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[36]  P. Vasseur,et al.  Effects of peroxisome proliferators and 12‐O‐tetradecanoyl phorbol‐13‐acetate on intercellular communication and connexin43 in two hamster fibroblast systems , 1997, International journal of cancer.

[37]  B. Kleinschmidt-DeMasters,et al.  Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms , 2000, Cancer Gene Therapy.

[38]  M. Takigawa,et al.  Dexamethasone induces apoptosis in proliferative chondrocytes through activation of caspases and suppression of the Akt-phosphatidylinositol 3'-kinase signaling pathway. , 2005, Endocrinology.

[39]  L. Pavelic,et al.  An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice. , 1997, Cancer gene therapy.

[40]  M. Merville,et al.  A cell type-specific and gap junction-independent mechanism for the herpes simplex virus-1 thymidine kinase gene/ganciclovir-mediated bystander effect. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.